0 288

Cited 0 times in

Rediscover the clinical value of small intestinal bacterial overgrowth in patients with intestinal Behçet's disease

Authors
 Jung Hyun Jo  ;  Soo Jung Park  ;  Jae Hee Cheon  ;  Tae Il Kim  ;  Won Ho Kim 
Citation
 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.33(2) : 375-379, 2018 
Journal Title
 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 
ISSN
 0815-9319 
Issue Date
2018
MeSH
Adult ; Anti-Infective Agents/administration & dosage ; Behcet Syndrome/drug therapy ; Behcet Syndrome/microbiology* ; Behcet Syndrome/physiopathology ; Breath Tests ; Cross-Sectional Studies ; Female ; Gastrointestinal Agents/administration & dosage ; Humans ; Intestinal Diseases/microbiology* ; Intestinal Diseases/physiopathology ; Intestine, Small/microbiology* ; Male ; Middle Aged ; Rifamycins/administration & dosage ; Surveys and Questionnaires ; Treatment Outcome
Keywords
Behçet's disease ; Hydrogen breath test ; Intestinal Behçet's disease ; Rifaximin ; Small intestinal bacterial overgrowth
Abstract
BACKGROUND AND AIMS: Many patients with intestinal Behçet's disease (BD) still suffer from gastrointestinal symptoms despite the disease being in endoscopic or radiological remission. Previous studies report that small intestinal bacterial overgrowth (SIBO) can be associated with inflammatory bowel disease. However, there have been no reports about SIBO in patients with intestinal BD. We sought to identify the frequency of SIBO in patients with inactive intestinal BD by hydrogen breath test (HBT) and to investigate the efficacy of rifaximin as a treatment for SIBO. METHODS: Twenty-five patients with intestinal BD who had gastrointestinal symptoms even in endoscopic or radiological remission status were enrolled between January 2012 and January 2016. The patients filled out a questionnaire regarding their subjective gastrointestinal symptoms and took an HBT. Patients with positive HBT results were recommended to take 800-mg rifaximin daily for 14 days. RESULTS: Nine patients (9/25, 36%) had a positive HBT test. Eight (8/9, 88.9%) were women, and their mean age was 48.7 years. The most common symptom was abdominal distension (8/9, 88.9%), followed by abdominal discomfort (6/9, 66.7%). Rifaximin was prescribed to the nine patients with positive HBT, but two patients refused to take the medication. Four weeks later, six of the seven patients taking rifaximin (85.7%) reported symptom improvement, and none of them reported adverse events. CONCLUSIONS: More than one-third of the patients with inactive intestinal BD who had gastrointestinal symptoms were accompanied by SIBO using HBT. Rifaximin might be an effective and safe drug to treat these patients.
Full Text
https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.13855
DOI
10.1111/jgh.13855
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Won Ho(김원호) ORCID logo https://orcid.org/0000-0002-5682-9972
Kim, Tae Il(김태일) ORCID logo https://orcid.org/0000-0003-4807-890X
Park, Soo Jung(박수정)
Jo, Jung Hyun(조중현) ORCID logo https://orcid.org/0000-0002-2641-8873
Cheon, Jae Hee(천재희) ORCID logo https://orcid.org/0000-0002-2282-8904
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/161799
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse